Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 803 results for "iibs"

TiGenix: TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition
TeleTrader.com

TiGenix: Transparency Information

GlobeNewswire 2015-07-31LEUVEN, Belgium, July 31, 2015 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major ... BizWire Express, 2 days ago
TiGenix: Dirk Buscher and Jose Terencio resign from TiGenix board of directors Franklin Credit Management Corporation, 2 days ago
[x]  

REG-TiGenix: Transparency Information

REGULATED INFORMATION PRESS RELEASE Transparency Information Leuven (BELGIUM) - July 31, 2015 - TiGenix NV (Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the ...
 Reuters2 days ago TiGenix: Transparency Information  EuroInvestor2 days ago TIGENIX : Transparency Information  4 Traders2 days ago

Cytokinetics Upgraded by Zacks to Hold (CYTK)

Zacks upgraded shares of Cytokinetics (NASDAQ:CYTK) from a powerful sell evaluation to some hold evaluation in a research note launched on Thursday, Marketbeat.com reports. Based on Zacks, Cytokinetics is a late-stage biopharmaceutical company ...
 WKRB News2 days ago Cytokinetics Cut to Strong Sell at Zacks (CYTK)  SleekMoney1 week ago MLV & Co. Reaffirms Buy Rating for Cytokinetics (CYTK)  WKRB News1 week ago Cytokinetics Trading 4.7% Higher After Analyst Upgrade (CYTK)  SleekMoney1 week ago
SleekMoney

PRA Health Sciences Upgraded by Zacks to Buy (PRAH)

Zacks upgraded shares of PRA Health Sciences (NASDAQ:PRAH) from a hold rating to a buy rating in a report released on Thursday morning, MarketBeat.Com reports. The brokerage currently has $47.00 target price on the stock. According to Zacks, PRA ...
 WKRB News3 days ago PRA Health Sciences Price Target Raised to $46.00 at Jefferies Group (PRAH)  SleekMoney1 week ago PRA Health Sciences Given Consensus Rating of Buy by Analysts (NASDAQ:PRAH)  WKRB News1 week ago

DuPont Fabros Technology's (DFT) CEO Chris Eldredge Q2 2015 Results - Earnings Call Transcript

Operator Welcome to the DuPont Fabros Second Quarter 2015 Earnings Call and Webcast [Operator Instructions]. I would now like to turn the conference call over to Mr. Chris Warnke, Manager of Investor Relations. The floor is yours, sir. Chris ...
 Seeking Alpha3 days ago Edited Transcript of CORI earnings conference call or presentation 29-Jul-15 8:30pm GMT  Yahoo! News3 days ago Cytokinetics' (CYTK) CEO Robert Blum on Q2 2015 Results - Earnings Call Transcript  Seeking Alpha4 days ago Eli Lilly's (LLY) CEO John Lechleiter on Q2 2015 Results - Earnings Call Transcript  Seeking Alpha1 week ago

Avraham Pharmaceuticals Updates on Successful 2nd Interim Results in Phase 2b Study of Ladostigil [Health & Beauty Close - Up]

Avraham Pharmaceuticals reported successful second interim results in a Phase 2b clinical trial for the evaluation of the safety and efficacy of ladostigil, for the treatment of mild cognitive impairment (MCI). After two years of treatment, the ...
 Pharmacy Choice4 days ago Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment  EON: Enhanced Online News6 days ago Avraham Pharmaceuticals Ltd. Announces Successful Second Interim Results In Phase IIb Study Of Ladostigil For The Treatment Of Mild Cognitive Impairment  BioSpace5 days ago Two positive Phase II studies announced at Alzheimer's Association International Conference  Pharma Letter1 week ago
[x]  
Case Reports in Oncology

Easy Diagnosis of Aortic Invasion in Patients with Lung Cancer Using Cine Magnetic Resonance Imaging

Selecting the proper treatment strategy for locally advanced lung cancer, such as T4 tumors, is difficult. Therefore, obtaining an accurate diagnosis of T4 tumors is required. It can be difficult to determine whether the tumor invades adjacent ...
 Case Reports in Oncology3 days ago

Eagle Pharmaceuticals RTU Bivalirudin NDA Accepted for Filing

"We look forward to the FDA's decision on this NDA in March 2016 and, if approved, intend to launch our RTU bivalirudin product the following day" WOODCLIFF LAKE, N.J., Jul 23, 2015 (BUSINESS WIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ...
 Noodls3 days ago Eagle Pharmaceuticals' NDA for RTU bivalirudin accepted by the US FDA for treating PCI and PTCA  Bloomberg1 week ago Eagle Pharmaceuticals Announces FDA Accepts RTU Bivalirudin NDA for Filing  Benzinga.com1 week ago Eagle Pharmaceuticals? RTU Bivalirudin NDA accepted for filing by FDA [Moj News Agency (Iran)]  Pharmacy Choice1 week ago
[x]  

Joint USAF/NOAA Solar Geophysical Activity Report and Forecast 30 July 2015

Status Report From: Space Weather Prediction Center (NOAA) Joint USAF/NOAA Solar Geophysical Activity Report and Forecast SDF Number 211 Issued at 2200Z on 30 Jul 2015 IA. Analysis of Solar Active Regions and Activity from 29/2100Z to ...
 SpaceRef3 days ago
European Pharmaceutical Review

Orgenesis, Inc. (ORGS: OTCQB) | Orgenesis Subsidiary MaSTherCell to Manufacture TxCell's Lead Product Ovasave for Multi-National Phase 2b Trial

- Orgenesis Inc. ( OTCQB : ORGS ), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today ...
 OTC Markets5 days ago MaSTherCell to manufacture TxCell's lead product Ovasave  European Pharmaceutical Review5 days ago TXCELL : Appoints MaSTherCell for the Manufacturing of Lead Product Ovasave®  4 Traders5 days ago FDA grants Fast Track Designation to TxCell's Ovasave for treatment of Crohn's disease  News-Medical.Net6 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less